Misplaced Pages

Asunaprevir

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Compound

Pharmaceutical compound
Asunaprevir
Clinical data
Other namesBMS-650032
ATC code
Identifiers
IUPAC name
  • tert-butyl N-carbamoyl]pyrrolidin-1-yl]-3,3-dimethyl-1-oxobutan-2-yl]carbamate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.206.482 Edit this at Wikidata
Chemical and physical data
FormulaC35H46ClN5O9S
Molar mass748.29 g·mol
3D model (JSmol)
SMILES
  • CC(C)(C)(C(=O)N1C(C1C(=O)N2(C2C=C)C(=O)NS(=O)(=O)C3CC3)OC4=NC=C(C5=C4C=C(C=C5)Cl)OC)NC(=O)OC(C)(C)C
InChI
  • InChI=InChI=1S/C35H46ClN5O9S/c1-9-19-16-35(19,31(44)40-51(46,47)22-11-12-22)39-28(42)25-15-21(49-29-24-14-20(36)10-13-23(24)26(48-8)17-37-29)18-41(25)30(43)27(33(2,3)4)38-32(45)50-34(5,6)7/h9-10,13-14,17,19,21-22,25,27H,1,11-12,15-16,18H2,2-8H3,(H,38,45)(H,39,42)(H,40,44)/t19-,21-,25+,27-,35-/m1/s1
  • Key:XRWSZZJLZRKHHD-WVWIJVSJSA-N


Asunaprevir (formerly BMS-650032, brand name in Japan and Russia Sunvepra) is an experimental drug candidate for the treatment of hepatitis C. It was undergoing development by Bristol-Myers Squibb and has completed Phase III clinical trials in 2013.

Asunaprevir is an inhibitor of the hepatitis C virus enzyme serine protease NS3. Asunaprevir is being tested in combination with pegylated interferon and ribavirin, as well as in interferon-free regimens with other direct-acting antiviral agents including daclatasvir.

References

  1. "Sunvepra (asunaprevir) soft gelatin capsules 100 mg. Registration certificate". State Register of Medicines (in Russian). Retrieved 26 August 2015.
  2. "A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients". ClinicalTrials.gov. 23 September 2015.
  3. C. Reviriego (2012). "Asunaprevir. HCV serine protein NS3 inhibitor, Treatment of hepatitis C virus". Drugs of the Future. 37 (4): 247–254. doi:10.1358/dof.2012.037.04.1789350.
  4. Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. (January 2012). "Preliminary study of two antiviral agents for hepatitis C genotype 1". The New England Journal of Medicine. 366 (3): 216–24. doi:10.1056/NEJMoa1104430. PMID 22256805.
  5. "Bristol-Myers' Daclatasvir, Asunaprevir Cured 77%: Study". Bloomberg. 19 April 2012.
  6. AASLD: Daclatasvir plus Asunaprevir Rapidly Suppresses HCV in Prior Null Responders Archived 2015-02-08 at the Wayback Machine. Highleyman, L. HIVandHepatitis.com. 8 November 2011.
RNA virus antivirals (primarily J05, also S01AD and D06BB)
Hepatitis C
NS3/4A protease inhibitors (–previr)
NS5A inhibitors (–asvir)
NS5B RNA polymerase inhibitors (–buvir)
Combination drugs
Hepatitis D
Picornavirus
Anti-influenza agents
Multiple/general
Interferon
3CL protease inhibitors (–trelvir)
RNA pol inhibitors
Multiple/Unknown/Other


Stub icon

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: